- Home
- GPGI vs BLLN Comparison
GPGI vs BLLN Comparison
Compare GPGI & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPGI | BLLN |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.6B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GPGI | BLLN |
|---|---|---|
| Price | $13.51 | $99.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $126.71 |
| AVG Volume (30 Days) | ★ 1.2M | 808.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.07% | N/A |
| EPS Growth | N/A | ★ 103.40 |
| EPS | N/A | ★ 0.48 |
| Revenue | $59,824,000.00 | ★ $305,112,000.00 |
| Revenue This Year | $768.10 | $46.29 |
| Revenue Next Year | $126.25 | $30.14 |
| P/E Ratio | ★ N/A | $208.49 |
| Revenue Growth | N/A | ★ 99.97 |
| 52 Week Low | $11.22 | $61.96 |
| 52 Week High | $25.66 | $150.44 |
Technical Indicators
Market Signals| Indicator | GPGI | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 40.74 |
| Support Level | $13.05 | $88.26 |
| Resistance Level | $13.07 | $97.36 |
| Average True Range (ATR) | 0.68 | 5.34 |
| MACD | -0.08 | -0.81 |
| Stochastic Oscillator | 21.41 | 48.79 |
Price Performance
Historical ComparisonAbout GPGI GPGI Inc.
GPGI Inc is a diversified holding permanent capital platform designed to acquire, own, and scale high-quality businesses that hold great positions in good industries.
About BLLN BillionToOne Inc.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.